The first line of defence

The first line of defence

Playing this cross-functional role is the main challenge for NPP. NPP adds a commercial aspect to a project, but [Cameron Tew] explained: "Though the commercial teams provide input into development, commercial values can take a backseat in organisations focused on the R&D aspects of product...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical technology Europe 2010-05, Vol.22 (5), p.11
1. Verfasser: Tew, Cameron
Format: Artikel
Sprache:eng
Schlagworte:
Best practice
Centralization
Clinical trials
Control
Management
Methods
New product failure
Pharmaceutical industry
Prevention
Product development
R&D
Research & development
Risk management
Support groups
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page 11
container_title Pharmaceutical technology Europe
container_volume 22
creator Tew, Cameron
description Playing this cross-functional role is the main challenge for NPP. NPP adds a commercial aspect to a project, but [Cameron Tew] explained: "Though the commercial teams provide input into development, commercial values can take a backseat in organisations focused on the R&D aspects of product development, in fact, it is not uncommon for R&D and NPP to speak different languages and have different priorities that can prevent the two groups from understanding and fully valuing each other."
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_763294054</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A231021979</galeid><sourcerecordid>A231021979</sourcerecordid><originalsourceid>FETCH-LOGICAL-g1694-5dee620e8f0d52babde46c509d86d21d8e091a330c6abafc95e1f05b3cf9f16c3</originalsourceid><addsrcrecordid>eNpt0M1qwzAMAGAfNljX9QF2C9t1Gf6JnfhYyrYOCru05-DYcuqSOluUvP8M3aGDIJBAfJJAN2TBSinyUqvyjtwjnihNDSkW5HF_hMyHAcesCxGy3mcOPEQLD-TWmw5h9VeX5PD-tt9s893Xx-dmvctbpnSRSwegOIXKUyd5YxoHhbKSalcpx5mrgGpmhKBWmcZ4qyUwT2UjrNeeKSuW5Omy93vofybAsT710xDTybpUguuCyiKh5wtqTQd1iL4fB2PPAW295oJRznSpk8pnVAsRBtP1EXxI7X_-dcancHAOdnbg5WqgmTC9DFPC0B5HbM2EeM1_AU-gcAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>763294054</pqid></control><display><type>article</type><title>The first line of defence</title><source>EBSCOhost Business Source Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Tew, Cameron</creator><creatorcontrib>Tew, Cameron</creatorcontrib><description>Playing this cross-functional role is the main challenge for NPP. NPP adds a commercial aspect to a project, but [Cameron Tew] explained: "Though the commercial teams provide input into development, commercial values can take a backseat in organisations focused on the R&amp;D aspects of product development, in fact, it is not uncommon for R&amp;D and NPP to speak different languages and have different priorities that can prevent the two groups from understanding and fully valuing each other."</description><identifier>ISSN: 1753-7967</identifier><language>eng</language><publisher>Monmouth Junction: Intellisphere, LLC</publisher><subject>Best practice ; Centralization ; Clinical trials ; Control ; Management ; Methods ; New product failure ; Pharmaceutical industry ; Prevention ; Product development ; R&amp;D ; Research &amp; development ; Risk management ; Support groups</subject><ispartof>Pharmaceutical technology Europe, 2010-05, Vol.22 (5), p.11</ispartof><rights>COPYRIGHT 2010 Intellisphere, LLC</rights><rights>Copyright Advanstar Communications, Inc. May 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Tew, Cameron</creatorcontrib><title>The first line of defence</title><title>Pharmaceutical technology Europe</title><description>Playing this cross-functional role is the main challenge for NPP. NPP adds a commercial aspect to a project, but [Cameron Tew] explained: "Though the commercial teams provide input into development, commercial values can take a backseat in organisations focused on the R&amp;D aspects of product development, in fact, it is not uncommon for R&amp;D and NPP to speak different languages and have different priorities that can prevent the two groups from understanding and fully valuing each other."</description><subject>Best practice</subject><subject>Centralization</subject><subject>Clinical trials</subject><subject>Control</subject><subject>Management</subject><subject>Methods</subject><subject>New product failure</subject><subject>Pharmaceutical industry</subject><subject>Prevention</subject><subject>Product development</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><subject>Risk management</subject><subject>Support groups</subject><issn>1753-7967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>N95</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpt0M1qwzAMAGAfNljX9QF2C9t1Gf6JnfhYyrYOCru05-DYcuqSOluUvP8M3aGDIJBAfJJAN2TBSinyUqvyjtwjnihNDSkW5HF_hMyHAcesCxGy3mcOPEQLD-TWmw5h9VeX5PD-tt9s893Xx-dmvctbpnSRSwegOIXKUyd5YxoHhbKSalcpx5mrgGpmhKBWmcZ4qyUwT2UjrNeeKSuW5Omy93vofybAsT710xDTybpUguuCyiKh5wtqTQd1iL4fB2PPAW295oJRznSpk8pnVAsRBtP1EXxI7X_-dcancHAOdnbg5WqgmTC9DFPC0B5HbM2EeM1_AU-gcAA</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Tew, Cameron</creator><general>Intellisphere, LLC</general><general>MultiMedia Healthcare Inc</general><scope>N95</scope><scope>XI7</scope><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7XB</scope><scope>883</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>KB0</scope><scope>L.-</scope><scope>M0F</scope><scope>NAPCQ</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20100501</creationdate><title>The first line of defence</title><author>Tew, Cameron</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g1694-5dee620e8f0d52babde46c509d86d21d8e091a330c6abafc95e1f05b3cf9f16c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Best practice</topic><topic>Centralization</topic><topic>Clinical trials</topic><topic>Control</topic><topic>Management</topic><topic>Methods</topic><topic>New product failure</topic><topic>Pharmaceutical industry</topic><topic>Prevention</topic><topic>Product development</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><topic>Risk management</topic><topic>Support groups</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tew, Cameron</creatorcontrib><collection>Gale Business: Insights</collection><collection>Business Insights: Essentials</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Trade &amp; Industry (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Trade &amp; Industry</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Pharmaceutical technology Europe</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tew, Cameron</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The first line of defence</atitle><jtitle>Pharmaceutical technology Europe</jtitle><date>2010-05-01</date><risdate>2010</risdate><volume>22</volume><issue>5</issue><spage>11</spage><pages>11-</pages><issn>1753-7967</issn><abstract>Playing this cross-functional role is the main challenge for NPP. NPP adds a commercial aspect to a project, but [Cameron Tew] explained: "Though the commercial teams provide input into development, commercial values can take a backseat in organisations focused on the R&amp;D aspects of product development, in fact, it is not uncommon for R&amp;D and NPP to speak different languages and have different priorities that can prevent the two groups from understanding and fully valuing each other."</abstract><cop>Monmouth Junction</cop><pub>Intellisphere, LLC</pub></addata></record>
fulltext fulltext
identifier ISSN: 1753-7967
ispartof Pharmaceutical technology Europe, 2010-05, Vol.22 (5), p.11
issn 1753-7967
language eng
recordid cdi_proquest_journals_763294054
source EBSCOhost Business Source Complete; EZB-FREE-00999 freely available EZB journals
subjects Best practice
Centralization
Clinical trials
Control
Management
Methods
New product failure
Pharmaceutical industry
Prevention
Product development
R&D
Research & development
Risk management
Support groups
title The first line of defence
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A39%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20first%20line%20of%20defence&rft.jtitle=Pharmaceutical%20technology%20Europe&rft.au=Tew,%20Cameron&rft.date=2010-05-01&rft.volume=22&rft.issue=5&rft.spage=11&rft.pages=11-&rft.issn=1753-7967&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA231021979%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=763294054&rft_id=info:pmid/&rft_galeid=A231021979&rfr_iscdi=true